Core Biomedicine

Targeting cancer's core lineage pathways beyond genomics

United States · $30.9M raised

Employees
1–10
Business Model
B2B
Total Funding
$30.9M
Last Round
$21.0M Series AJul 2026
Rounds
2

About

CORE Biomedicine is a preclinical-stage oncology company developing precision medicine therapeutics that target core lineage-dependent pathways in cancer cells, moving beyond conventional genomic approaches. The company's scientific rationale is that tumors depend on specific lineage transcription programs, and disrupting these core pathways can halt cancer progression in ways that genomic-targeted therapies cannot. CORE Biomedicine was incubated at Harvard Innovation Labs and is backed by UTokyo IPC, focusing on advancing novel cancer lineage therapeutics toward clinical development.

Summary

Core Biomedicine is a Biotech company based in United States. It has raised $30.9M in total across 2 rounds, most recently a $21.0M Series A round in Jul 2026. Investors include UTokyo Innovation Platform.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series ASeries AJul 2026
$21.0M

Sign up to see all 2 rounds

Seed through Series A — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Core Biomedicine on Indexed.vc
<a href="https://indexed.vc/companies/core-biomedicine"><img src="https://indexed.vc/api/badge/company/core-biomedicine" alt="Core Biomedicine on Indexed.vc" width="260" height="76" /></a>